vanced applications that use these channels as the target for tissue engineering, which may offer the hope of tissue regeneration in the future, will also be explored.
| INTRODUC TI ON
Voltage-gated calcium channels (VGCCs) are heteromeric membrane protein complexes characterized by depolarization-induced calcium entry, which render the membrane highly permeable for Ca 2+ ions (Figure 1 ). Based on their electrophysiological properties, VGCCs can be divided into low-and high-voltage activated channels. The L-type voltage-gated calcium channels (L-VGCCs), a major route of calcium influx, is a part of the high-voltage activated family. 1 They were named "L" for their long-lasting inward currents during the depolarization process as studied in neurons and cardiac myocytes, and they are sensitive to 1,4-dihydropyridines.
The Ca 2+ current mediated by L-VGCCs can be stimulated by Bay K 8644 and FPL 64176, or blocked by nifedipine and nimodipine. properties of the calcium currents. 8 It also takes part in cell attachment of skeletal myocytes and synaptogenesis in neurons. 5 The β subunit is a cytoplasmic protein containing a conserved Src homology 3 (SH3) domain and a guanylate kinase-like domain. It binds to the cytoplasmic linker between domains I and II of the α1 subunit via the guanylate kinase domain and facilitates trafficking of calcium channel complexes by preventing E3 ubiquitin ligase-induced proteasomal degradation of the α1 subunit. 6, 9 The γ subunit was purified from skeletal muscle, but it can be absent, especially in heart tissue. Compared with other auxiliary subunits, its role is limited and defined as a transmembrane AMPA-glutamate receptor modifying protein. 6 All these subunits can undergo alternative splicing, a process that enables a single gene to code for multiple proteins by rearranging the pattern of introns and exons. This process is a key mechanism for the regulation of pharmacological properties of LVGCCs, generating a variety of unique splice isoforms with distinct cell and tissue distribution, with significance for specific physiological and pathological processes. 10, 11 According to differences of the α1 subunits, L- 
| L-VG CC S AND MSC S
Mesenchymal stem cells are multipotent cells that have a wide distribution in several tissues including bone marrow, adipose and dental tissues, and have the ability to differentiate into a large number of cell types including osteoblasts and adipocytes, as well as chondrocytes and neurons. 33 Table 1 . 
| L-VGCCs and bone marrow-derived mesenchymal stem cells

| L-VGCCs and dental MSCs
Dental tissues are accessible resources that provide an abundant reservoir of MSCs, such as dental pulp stem cells (DPSCs), stem cells from exfoliated deciduous teeth (SHED), stem cells from the apical papilla (SCAPs) and periodontal ligament stem cells (PDLSCs). To date, many studies have investigated the involvement of L-VGCCs in regulating the functions of dental MSCs. DPSCs are derived from dental pulp and possess the capacity for multi-lineage differentiation towards bone, cartilage and fat. 41 Studies have been indicated that the L-VGCCs blocker nimodipine inhibits the odontogenic differentiation of DPSCs from rats, and knock-down of Ca v 1.2 can inhibit the differentiation of rDPSCs. 42 Furthermore,
Li et al found that L-VGCCs promote the expression of dentin sialophosphoprotein (DSPP) and odontoblastic differentiation of DPSCs from humans. 43 They also found that the enhanced odontoblastic differentiation of DPSCs was regulated by L-VGCCs through the Smad1/5/8 and Erk1/2 pathways. 43 However, recent experiments by Mizumachi et al suggest that the calcium-sensing receptor-ERK signalling rather than L-VGCCs is responsible for the observed effect on odontogenic differentiation of human dental pulp cells, indicating the involvement of different pathways in each cell type. 44 Recently, a novel population of MSCs was discovered in the apical papilla, the SCAPs. These stem cells were demonstrated to have a stronger ability of odontogenic differentiation and continued root formation compared to DPSCs. 45 In rat SCAPs, 
| L-VGCCs and MSCs from other tissues
In addition to the bone marrow, MSCs also exist in many other tissues, including adipose and skin tissues. 
| L-VG CC S AND N SC S
Neurogenesis is a process with several stages such as prolifera- Ca v 1.3 knock-down rats produced using adeno-associated virus (AAV) or retrovirus-based technologies showed impaired dendritic or axonal formation in vivo. 63 To further study the mechanism of the regulation of neurogenic activities by L-VGCCs, researchers investigated the involvement of Ca 2+ -dependent regulatory genes in differentiation, such as BETA2/NeuroD1, 64 which are essential to neuronal survival and/or maturation in many neuronal tissues, including the dentate hippocampus, the cerebellum and the olfactory bulb, 67, 68 and the research showed that BETA2/NeuroD1 were involved in L-VGCCs-mediated regulation. Moreover, it has been reported that activation of the GABA B receptor can increase Ca v 1.3 expression in NSCs, 69 suggesting that GABA receptors may be a part of a signalling pathway for stem cell maintenance. The depolarization mediated by glutamate and GABA A receptors would facilitate the Ca 2+ influx through L-type Ca 2+ channels. 64 However, the role of GABA receptors in the regulation of L-VGCCs is controversial, since the evidence indicating that GABA receptors may be involved in the maintenance and activation of hippocampal NSCs is inconsistent 70 .
| L-VG CC S AND OTHER S TEM CELL S
Cardiac progenitor cells (CPCs), which are mainly located in the myocardium, express the cardiogenic genes. 
| P OTENTIAL APPLI C ATI ON S OF L-VG CC S IN TISSUE ENG INEERING
Tissue engineering is an emerging interdisciplinary field involving the use of an interactive triad of scaffolds, signalling molecules, engineering and cells, focusing on producing functional replacement tissues and creating favourable conditions for tissue regeneration. 75 The latest developments in tissue engineering have provided new perspectives for the regeneration and replacement of defective tissues, such as bone and heart tissue. 76 Signalling molecules, which are vital for all tissue engineering strategies, can promote spatiotemporal signalling cascades to maximize the functionality of engineered tissues. 77 Given that L-VGCCs are of significance for the osteogenic, myogenic and neural differentiation of several stem cell types, we will focus on their potential applications in the tissue engineering of bone, heart and neurons for organ repair and regeneration (Figure 3 ).
| L-VGCCs and bone tissue engineering
Large bone defects caused by trauma, infections and other causes 78 abrogate the bone's ability for spontaneous healing and consequently pose a great challenge for clinical treatment. 79 Bone tissue engineering is a promising solution for treating such defects by providing a scaffold, combined with signalling molecules and cells, to guide the regeneration of osseous tissue. 80 Application of scaffolds loaded with biological molecules that stimulate cell proliferation and osteogenic differentiation is one of the most investigated techniques for promoting the bone formation ability. 81 Several biomolecules, such as bone morphogenetic proteins (BMPs), Wnt signalling molecules and transforming growth factor-β (TGF-β), have been applied in the regulation of osteogenesis to enhance bone healing. 79, 80 Currently, some studies showed that MAPK and Wnt signalling path- 
| L-VGCCs and cardiomyogenesis
Heart failure, especially myocardial infarction, is one of the leading global health challenges that threaten the well-being of more than thirty million people annually. 84 Resident cardiomyocytes of patients with heart disease have a compromised proliferation and differentiation potential. Current strategies for treating heart dysfunction, such as organ transplantation, are limited due to immunological rejection and insufficient availability of donor organs. 85 Tissue engineering has emerged as a promising therapeutic strategy for cardiac regeneration. To date, diverse cell sources have been adopted for repair and regeneration of the impaired myocardium in animal models, with a subset of them undergoing clinical assessment.
86
Stem cell-based therapy has been considered as an attractive option for treating defective myocardium. 87, 88 Several stem cell types have been used in clinical trials for treating functional deficiency of the heart, such as CPCs. A modest improvement of cardiac performance was observed in several clinical trials, but the methodology is still inadequate, partly due to functional immaturity and electrical insufficiency. 83 The addition of small-molecule compounds in tissue engineering is favourable to structural and functional recovery of the treated hearts. 89 However, this approach is complicated by the fact that heart regeneration is a process involving cell proliferation, differentiation and maturation. 90 Adequate knowledge about the regulatory processes that are active during cardiomyogenesis is indispensable for using biomolecules with unique activity to target stem cell function. from the sarcoplasmic reticulum through type-2 ryanodine receptors (RyR2), which is essential for myocardial excitation-contraction coupling activity, and loss-of-function mutations of L-VGCCs can lead to cardiac failure. 93, 94 Some scholars have investigated 
| L-VGCCs and neurogenesis
Since adult NSCs are limited in differentiation and distribution, neurons are refractory to replication. The reprogramming or regeneration of human neural tissue 96 is considered to be difficult to achieve. 
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